Based on the new resultsRoche is planning to launch a late-stage trial of its PD-L1 inhibitor in lung-cancer patients, while Bristol-Myers is moving its combinationregimen into late-phase studies as well.
Thirty-one percent of telaprevir patients who had gotten no benefit at all from previous treatments with the current hepatitis C regimen, a combination of interferon and antiviral drug ribavirin, had SVRs.
Therefore healthcare professionals should switch patients who are on Tekturna or any aliskiren-based products, in combination with an ACE or an ARB, to an alternative anti-hypertension regimen.